Autopsy report · NCT07566585

Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation

“Company Decision”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

BlueSphere Bio, Inc

Sponsor type

Industry

Conditions

AML - Acute Myeloid Leukemia; AML With Mutated NPM1; AML, Adult Recurrent

Interventions

SOC+ BSB-2002; SOC+BSB-2002

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• 3D011-08 Monotherapy in Subjects With Advanced Solid Tumors
  “Company's decision” (97% match in meaning)
• Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)
  “Company business decision” (92% match in meaning)
• A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
  “Corporate decision” (90% match in meaning)
• HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
  “Business decision” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.